Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | PRODUCT CODE: 1782823

Cover Image

PUBLISHER: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | PRODUCT CODE: 1782823

Liver Metastases Treatment

PUBLISHED:
PAGES: 370 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Liver Metastases Treatment Market to Reach US$4.7 Billion by 2030

The global market for Liver Metastases Treatment estimated at US$3.4 Billion in the year 2024, is expected to reach US$4.7 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$924.6 Million While China is Forecast to Grow at 9.0% CAGR

The Liver Metastases Treatment market in the U.S. is estimated at US$924.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$953.7 Million by the year 2030 trailing a CAGR of 9.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Liver Metastases Treatment Market - Key Trends & Drivers Summarized

What Are the Most Effective Treatment Modalities for Liver Metastases?

Liver metastases, secondary tumors that spread to the liver from other primary cancer sites, present a complex therapeutic challenge. Treatment modalities vary depending on tumor size, location, and the patient’s overall health condition. Traditionally, surgical resection has been the gold standard for patients with limited metastases and good liver function. Hepatectomy, though effective, is only feasible for a small percentage of patients due to the multifocal nature of metastases. In cases where surgery is not an option, alternative approaches like radiofrequency ablation (RFA) and microwave ablation (MWA) are increasingly used, offering a minimally invasive solution to target small tumors with thermal destruction. Additionally, transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) have gained traction, particularly for patients with inoperable tumors, by delivering high-dose localized chemotherapy or radiation directly to the liver while minimizing systemic toxicity. Immunotherapy, though still in its early stages for liver metastases, has shown promise, with checkpoint inhibitors like pembrolizumab and nivolumab improving survival rates in select patients. Systemic therapies, particularly targeted treatments like monoclonal antibodies and tyrosine kinase inhibitors, have revolutionized treatment by blocking molecular pathways essential for cancer cell proliferation. Moreover, stereotactic body radiotherapy (SBRT) has emerged as a viable non-surgical option, particularly in patients with oligometastatic disease. Personalized medicine, leveraging genetic profiling, is increasingly shaping treatment selection, allowing oncologists to tailor therapies based on tumor biology rather than relying on a one-size-fits-all approach. The evolution of combination therapies-where multiple modalities such as chemotherapy, radiation, and targeted agents are used in tandem-has significantly improved progression-free survival rates, particularly for colorectal cancer liver metastases (CRLM).

How Are Advancements in Precision Medicine Transforming Liver Metastases Management?

Precision medicine has significantly altered the treatment landscape for liver metastases by integrating molecular diagnostics, predictive analytics, and targeted therapies. The advent of liquid biopsy techniques, which detect circulating tumor DNA (ctDNA) in blood samples, has revolutionized early detection and real-time treatment monitoring. Liquid biopsies allow for non-invasive tracking of tumor evolution, facilitating timely adjustments to therapeutic strategies and enabling the early identification of resistance mechanisms. Molecular profiling of tumors has led to the development of personalized therapies, such as KRAS and BRAF inhibitors for colorectal cancer metastases and HER2-targeted treatments for breast cancer liver metastases. Artificial intelligence (AI) and machine learning algorithms are further refining treatment strategies by analyzing vast datasets to predict individual responses to specific therapies, minimizing trial-and-error approaches in oncologic decision-making. Additionally, AI-driven imaging technologies are enhancing tumor visualization and treatment planning, allowing for more precise radiation and interventional oncology procedures. Another significant breakthrough is the rise of theranostics, where diagnostic imaging agents and therapeutic drugs are combined to deliver a highly targeted attack on metastatic cells. Lutetium-177 and Yttrium-90-based radioisotope therapies are gaining recognition for their efficacy in treating neuroendocrine and colorectal liver metastases. Furthermore, the integration of organoid-based research-where patient-derived tumor cells are grown in lab environments to test drug efficacy-holds the potential to refine precision oncology further. The increasing role of predictive biomarkers, such as microsatellite instability (MSI) status and tumor mutational burden (TMB), has also played a pivotal role in shaping immunotherapy applications, ensuring that only the most responsive patient populations receive these costly but highly effective treatments. These innovations collectively underscore a shift towards highly individualized, data-driven treatment strategies that promise improved survival outcomes and reduced treatment-related toxicity.

Is Minimally Invasive Therapy the Future of Liver Metastases Treatment?

The shift toward minimally invasive procedures in liver metastases treatment has been one of the most defining trends in oncology. Conventional surgical resection, though effective, comes with significant risks, longer hospital stays, and higher complication rates, leading to an increased demand for less invasive options. Interventional radiology has paved the way for breakthroughs like percutaneous ablation techniques-radiofrequency ablation (RFA) and microwave ablation (MWA)-which have demonstrated comparable survival benefits for patients with limited metastases while reducing procedure-related morbidity. Cryoablation, though less widely used, is gaining traction due to its ability to preserve surrounding tissue integrity while effectively destroying tumor cells. The widespread adoption of laparoscopic and robotic-assisted surgery has further revolutionized the field by allowing for enhanced precision, smaller incisions, and quicker recovery times. Transarterial therapies, such as chemoembolization (TACE) and radioembolization (TARE), have become standard-of-care approaches for patients with unresectable liver metastases, particularly in colorectal and hepatocellular carcinoma cases. The growing use of robotic-assisted interventions, including robotic liver resections, has enabled surgeons to perform complex procedures with enhanced dexterity and minimal trauma to the patient. Nanotechnology-based drug delivery systems are also on the horizon, providing a means to administer chemotherapeutic agents directly to tumors with improved specificity, reducing systemic side effects. Moreover, high-intensity focused ultrasound (HIFU) is emerging as a promising non-invasive modality, leveraging sound waves to destroy cancerous tissue without the need for incisions or anesthesia. As healthcare systems continue to shift towards patient-centric care, the demand for outpatient-based, minimally invasive treatments is set to rise, offering a paradigm shift in how liver metastases are managed across global healthcare settings.

What Is Driving Growth in the Global Liver Metastases Treatment Market?

The growth in the liver metastases treatment market is driven by several factors, including advancements in targeted therapy, the increasing adoption of minimally invasive treatments, and a rising global cancer burden. The shift towards precision medicine, fueled by breakthroughs in genetic profiling and biomarker-driven therapies, has expanded the treatment landscape, allowing for personalized therapeutic strategies that yield superior clinical outcomes. Technological innovations in interventional radiology, such as robotic-assisted surgery and AI-powered imaging, are streamlining treatment procedures, making them more effective and accessible. The increasing prevalence of colorectal, breast, and lung cancers-primary contributors to liver metastases-is pushing the demand for novel therapeutic options. Moreover, the rising investment in oncology research and development, particularly in immunotherapy and combination therapies, is accelerating market expansion. Growing consumer preference for outpatient and minimally invasive procedures has led to increased adoption of techniques like radiofrequency ablation (RFA), transarterial chemoembolization (TACE), and stereotactic body radiotherapy (SBRT), further propelling market growth. The introduction of liquid biopsies and AI-driven diagnostics is enabling early detection, leading to improved patient stratification and treatment outcomes. Additionally, the surge in biopharmaceutical collaborations and strategic partnerships is fostering innovation, driving the commercialization of novel liver metastases therapies. Government initiatives supporting cancer research and access to advanced treatments in emerging economies are playing a crucial role in expanding market reach. The shift towards value-based healthcare models, where cost-effectiveness and patient quality of life are prioritized, has further fueled the demand for non-invasive and targeted therapies. Lastly, the growing awareness and adoption of clinical trials for experimental treatments, including next-generation immunotherapies and gene editing technologies, signal a future where liver metastases treatment is not only more effective but also increasingly tailored to individual patient needs.

SCOPE OF STUDY:

The report analyzes the Liver Metastases Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy); Primary Cancer (Colorectal Cancer, Breast Cancer); Distribution Channel (Hospital Pharmacies, Specialty Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • 89bio, Inc.
  • Akero Therapeutics
  • AstraZeneca
  • Bayer AG
  • Biocompatibles UK Ltd.
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals Ltd.
  • Delcath Systems, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech (a member of Roche Group)
  • Madrigal Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Plus Therapeutics, Inc.
  • Regeneron Pharmaceuticals
  • SillaJen, Inc.
  • Sirtex Medical Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP31872

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Liver Metastases Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Secondary Liver Tumors Throws the Spotlight on Advancements in Liver Metastases Treatment
    • Increasing Use of Precision Oncology and Genomic Profiling Drives Adoption of Targeted Therapy Approaches
    • OEM Innovation in Liver-Directed Therapies Such as TARE and TACE Strengthens Localized Treatment Modalities
    • Expansion of Immunotherapy Combinations Spurs New Pathways for Metastatic Liver Cancer Management
    • Growing Integration of Artificial Intelligence in Imaging and Planning Drives Surgical and Radiological Precision
    • Regulatory Approvals of New Systemic Therapies Accelerate Access to Multiline Treatment Protocols
    • OEM Development of Minimally Invasive Ablation Technologies Enhances Patient Recovery and Hospital Efficiency
    • Rising Use of Hepatic Artery Infusion Chemotherapy (HAIC) in Colorectal Liver Metastases Propels Procedural Uptake
    • Increased Adoption of Multidisciplinary Care Models Strengthens Coordination Across Oncology Specialties
    • OEM Partnerships With Academic Institutions Drive Development of Next-Generation Liver Metastases Treatment Protocols
    • Expansion of Transplant Eligibility Criteria for Selected Liver Metastases Patients Spurs Surgical Innovation
    • Surge in Biomarker-Driven Clinical Trials Generates New Therapeutic Targets in Hepatic Metastatic Cancers
    • OEM Emphasis on Personalized Dosimetry in Radiation Therapy Enhances Tumor Control and Reduces Toxicity
    • Growing Patient Awareness and Earlier Diagnosis Increase Candidate Pools for Curative Liver Interventions
    • Emergence of Radiomics and Predictive Modeling Supports Risk Stratification and Treatment Customization
    • Expansion of Proton Therapy and Stereotactic Techniques Strengthens Non-Invasive Treatment Options
    • Rising Need for Palliative Interventions in Advanced-Stage Patients Spurs Innovation in Comfort-Focused Procedures
    • OEM Investment in Drug-Eluting Beads and Precision Embolic Platforms Enhances Drug Delivery Efficiency
    • Globalization of Clinical Trial Participation Expands Market Access to Novel Liver Metastases Therapies
    • Focus on Real-World Evidence and Post-Market Surveillance Reinforces Long-Term Safety and Efficacy Validation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Liver Metastases Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Liver Metastases Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Liver Metastases Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Liver Metastases Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Specialty Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Specialty Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Specialty Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • JAPAN
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • CHINA
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • EUROPE
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Liver Metastases Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Liver Metastases Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Liver Metastases Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • FRANCE
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • GERMANY
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Italy 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 101: UK Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: UK 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 110: Spain Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Spain Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Spain 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 119: Russia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Russia Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Russia 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Liver Metastases Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Liver Metastases Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 15-Year Perspective for Liver Metastases Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 149: Australia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Australia Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Australia 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • INDIA
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 158: India Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: India Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: India 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 161: India Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 167: South Korea Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: South Korea Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: South Korea 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Asia-Pacific Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Asia-Pacific 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 185: Latin America Recent Past, Current & Future Analysis for Liver Metastases Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 186: Latin America Historic Review for Liver Metastases Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Latin America 15-Year Perspective for Liver Metastases Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 197: Argentina Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Argentina Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Argentina 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 206: Brazil Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Brazil Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Brazil 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 215: Mexico Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Mexico Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Mexico 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Rest of Latin America Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Rest of Latin America 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 233: Middle East Recent Past, Current & Future Analysis for Liver Metastases Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 234: Middle East Historic Review for Liver Metastases Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Middle East 15-Year Perspective for Liver Metastases Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 245: Iran Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Iran Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Iran 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 254: Israel Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Israel Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Israel 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Saudi Arabia Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Saudi Arabia 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 272: UAE Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: UAE Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: UAE 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Rest of Middle East Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: Rest of Middle East 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • AFRICA
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 290: Africa Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Africa Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Africa 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!